Aska Pharmaceutical Holdings Co., Ltd. · TSE:4886
Aska Pharmaceutical — FY2022 Earnings Presentation
62 slides from Aska Pharmaceutical's earnings presentation, May 18, 2023
Slide 1: Consolidated Financial Results for the Year Ended March 31, 2023 (FY2022)
May 18, 2023 Consolidated Financial Results for the Year Ended March 31, 2023 (FY2022) Presentation for Investors Stock code : 4886 (TSE) ASKA Pharmaceutical Holdings Co., Ltd.
Slide 2: Forward Looking Statement
Forward Looking Statement The forward-looking statements contained in this presentation are based on the Company’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Accordingly, there is a possibility that actual
Slide 3: Financial Results Summary for FY2022
Financial Results Summary for FY2022 Atsushi Maruo, Senior Managing Member of the Board of Directors, Represetative Director ASKA Pharmaceutical Holdings Co., Ltd. 3
Slide 4: FY2022 Financial Results Highlight
FY2022 Financial Results Highlight ✓ 60.4 billion yen, up 6.8% YOY, Achieved record sales Net sales Achieved record sales due to the expansion of the pharmaceutical business and the animal health business. ✓ 31.8 billion yen, ratio improved 0.7 percentage points YOY Cost of sales Product mix improve
Slide 5: Consolidated Statements of Income
Consolidated Statements of Income FY2021 FY2022 Actual +/- Growth +/- (Millions of yen) Actual Actual Net sales 56,607 60,461 3,853 6.8% Cost of sales 30,255 31,876 1,620 5.4% Gross profit 26,351 28,584 2,233 8.5% Selling, general and administrative expenses 21,556 23,476 1,920 8.9% Operating profit
Slide 6: Consolidated Net Sales by Business
Consolidated Net Sales by Business FY2021 FY2022 Breakdown Actual +/- Growth +/- (Millions of yen) Actual Actual Pharmaceutical business 50,791 53,579 88.6% 2,787 5.5% Animal health business 5,630 6,660 11.0% 1,030 18.3% Other businesses 185 220 0.4% 35 19.0% Total 56,607 60,461 100.0% 3,853 6.8% 6
Slide 7: Sales of Main Products (Pharmaceutical Business)
Sales of Main Products (Pharmaceutical Business) (Millions of yen) Products FY2021 FY2022 FY2023 Area Category Notes (FY2022) (generic name) Actual Actual YOY Forecast YOY CANDESARTAN *1 NHI drug price declined, but sales volume AG (candesartan) 12,394 10,723 -13.5% 9,268 -13.6% remained Internal Me
Slide 8: Sales by Major Business Field (ASKA Animal Health)
Sales by Major Business Field (ASKA Animal Health) (Millions of yen) FY2021 FY2022 FY2023 Business field Actual Actual YOY Forecast YOY Feed additives and Materials 3,508 4,152 18.3% 3,832 -7.7% Mixed feed Livestock pharmaceuticals 1,466 1,685 14.9% 1,680 -0.3% Key factors In addition to strong sa
Slide 9: Analysis of Operating Profit (YOY)
Analysis of Operating Profit (YOY) (Millions of yen) 4,795 5,108 629 491 2,233 486 313 FY2021 Increase in Increase in promotion Increase in Increase in Increase in FY2022 R&D expenses expenses, travel expenses, depreciation other expenses Actual gross profit Actual and transportation costs etc. Key
Slide 10: Consolidated Balance Sheet
Consolidated Balance Sheet End of FY2021 (Millions of yen) (Millions of yen) End of FY2022 (Millions of yen) Assets Current liabilities Current liabilities 16,011 17,650 Inventories +2,627 （+1,638） Non-current liabilities Investment securities +2,162 Current assets Non-current liabilities Current as
Slide 11: FY2023 Forecast (Consolidated)
FY2023 Forecast (Consolidated) FY2022 FY2023 YOY YOY (Millions of yen) Actual Forecast Actual +/- Growth +/- Net sales 60,461 62,000 1,538 2.5％ Operating profit 5,108 5,400 291 5.7％ Ordinary profit 5,232 5,500 267 5.1％ Profit attributable to owners of parent 4,238 4,400 161 3.8％ Major factors Net
Slide 12: Forecast of Operating Profit (YOY)
Forecast of Operating Profit (YOY) (Millions of yen) 5,400 5,108 254 438 616 82 58 FY2022 Increase in promotion Increase in Decrease in Increase in Decrease in FY2023 expenses, travel R&D expenses other expenses gross profit depreciation Actual expenses, and Forecast transportation costs etc. Analys
Slide 13: Capital Expenditures, Depreciation and R&D expenses
Capital Expenditures, Depreciation and R&D expenses Capital Expenditures Depreciation R&D expenses (Tangible and software transfer basis) (Tangible/intangible total) (Millions of yen) (Millions of yen) (Millions of yen) 4,227 4,309 3,598 3,127 2,885 2,702 1,256 1,345 657 FY2021 FY2022 FY2023 FY2021
Slide 14: PBR and ROE
PBR and ROE Change in our PBR and ROE over time PBR (multiple) PBR ROE (return on equity) ROE (%) 1.40 8.8 10.0 1.21 8.2 9.0 1.20 1.14 8.0 1.05 5.8 6.3 7.0 0.95 7.8 1.00 6.0 0.87 4.1 5.0 0.80 3.4 0.72 0.97 0.73 4.0 0.65 1.9 0.76 3.0 1.5 1.5 0.60 2.0 1.0 0.40 0.0 FY2013 FY2014 FY2015 FY2016 FY2017 FY
Slide 15: Image of Investment in Future Growth and Shareholders’ Return
Image of Investment in Future Growth and Shareholders’ Return Image of capital allocation during the Medium-Term Management Plan • Overseas business • Growth-oriented Fund raising • Investment in new areas procurement Growth investment (Femtech, etc.) • Establishment of CVC fund • Introduction, seed
Slide 16: Return to Shareholders/Cross-shareholdings
Return to Shareholders/Cross-shareholdings Shareholders’ return Changes in dividends per share Our basic policy is to pay stable and Payout ratio continuous dividends in order to return fair 74.0% profits to all of our shareholders. 20yen On the basis of recent conditions, we plan to increase the di
Slide 17: Promote ESG Management
Sustainability Promote ESG Management 17
Slide 18: Sustainability Structure and Efforts for Environment
Sustainability Structure and Efforts for Environment サステナビリティの更なる推進のため、2023年度より体制を強化する。（2023/03/06公表） Enhancing the structure from FY2023 to further promote Sustainability, including ESG management [Appointment of Board member in Charge] Atsushi Maruo, In Charge of Sustainability [Establishment of S
Slide 19: HR Development to Support the Fulfillment of Our Vision
HR Development to Support the Fulfillment of Our Vision 7 strategies for Medium-term Management Plan (7) Develop Human Resources to Realize Growth Strategies Construction of foundation to support growth HR strategies that promote growth Productivity improvement and employee engagement Acquisition of
Slide 20: Overview of FY2022 Initiatives for FY2023
Overview of FY2022 Initiatives for FY2023 Takashi Yamaguchi, President, Member of the Board, Representative Director ASKA Pharmaceutical Holdings Co., Ltd. 20
Slide 21: Overview of FY2022: 2nd year of the Medium-Term Management Plan
ASKA Pharmaceutical Holdings Co., Ltd. Overview of FY2022 2nd year of the Medium-Term Management Plan 21
Slide 22: The Goals of the Medium-Term Management Plan 2025
The Goals of the Medium-Term Management Plan 2025 "Become a Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company” The Medium-Term Management Plan 2025 Numerical Targets Net sales: 70 billion yen, Operating profit rate: 8%, ROE: 8% Based on below foundation, The Medium-Term
Slide 23: Medium-Term Management Plan 2025: Trends in Actual Results
Medium-Term Management Plan 2025: Trends in Actual Results Last year of previous plan 1st year of current plan 2nd year of current plan Last year of current plan FY2020 2021年3月期 FY2021 FY2022 FY2025 実績 Actual Actual Actual Targets Net sales (millions of yen) 55,181 56,607 60,461 70,000 Operating pro
Slide 24: Summary of the 2nd Year of the Medium-Term Management Plan 2025
Summary of the 2nd Year of the Medium-Term Management Plan 2025 The Medium-Term Management Plan 2025 Numerical Targets Net sales: 70 billion yen, Operating profit rate: 8%, ROE: 8% 2nd year of the Medium-Term Management Plan FY2022 Actual Net sales: 60.4 billion yen Operating profit 5.1 billion yen
Slide 25: Medium-Term Business Plan 2025: 7 Strategies, Results, and Future Efforts
Medium-Term Business Plan 2025: 7 Strategies, Results, and Future Efforts Strategies Results for FY2022 Future results and efforts (1) Enhancing Corporate Value by ・No. 1 company in Ob/Gyn area ・ Further penetration of RELUMINA Strengthening Initiatives in the ・Expanded share in LEP market through i
Slide 26: Medium-Term Business Plan 2025: Strategies, Results, and Future Efforts
Medium-Term Business Plan 2025: 7 Strategies, Results, and Future Efforts Strategies Results for FY2022 Future issues and efforts (5) Improving Operational Efficiency, ・Continuation of cost reduction measures ・Continued response to cost increases due to managing Costs, and Reinforcing ・Rethinking of
Slide 27: FY2023 Group Companies’ Initiatives
FY2023 Group Companies’ Initiatives 27
Slide 28: ASKA Pharmaceutical Co., Ltd.
ASKA Pharmaceutical Co., Ltd. ■Main initiatives ・Specialty Areas ・Development Pipeline ・Overseas Business Development 28
Slide 29: ASKA Pharmaceutical Co., Ltd.
ASKA Pharmaceutical Co., Ltd. ■Main initiatives ・Specialty Areas ・Development Pipeline ・Overseas Business Development 29
Slide 30: A Leading Company in Ob/Gyn Field
A Leading Company in Ob/Gyn Field ASKA Pharmaceutical Ob/Gyn product sales trend Aims for Financial results base further growth (Millions of yen) 22,000 16,728 14,593 12,387 8,846 FY2018 FY2019 FY2020 FY2021 FY2022 FY2025 Achieved 20 billion yen in sales of obstetrics and gynecology products ahead o
Slide 31: A Leading Company in Ob/Gyn Field
A Leading Company in Ob/Gyn Field We achieved top sales in the field of obstetrics Key factors for sales growth and gynecology in the 2nd half of FY2022 RELUMINA’s further growth Added indication for endometriosis As a leading company, we implemented Launch of DroEthi various initiatives, includ
Slide 32: Obstetrics and Gynecology Products by Life Stage
Obstetrics and Gynecology Products by Life Stage Early Puberty Sexual maturity Menopause Old age childhood Oral contraception Drospirenone (LF111) ANGE NORLEVO Menopause HOLIN Iron deficiency Riona (Co-Pro* ) anemia STD/infection Rapid SP Chlamydia (Co-pro*) Relugolix Combination Tablet（AKP-022） Ute
Slide 33: Growth Driver - RELUMINA (relugolix)
Growth Driver - RELUMINA (relugolix) RELUMINA sales trend Reality of treatment of endometriosis Aims for further (Estimation from electronic health insurance claims data) growth *Financial results base (millions of yen) Patients diagnosed as endometriosis (1,000,000 patients) 10,128 8,840 Patients【主
Slide 34: Further Contribution to the Treatment of Dysmenorrhea
Further Contribution to the Treatment of Dysmenorrhea LEP* market continues to expand Our LEP* formulations ■ ASKA products ■Competitors’ products In-house analysis based on date of Encise Inc. (unauthorized reproduction prohibited) FY2022 thousand 10,010 sheets Factors in Market Share Gain FY2020 A
Slide 35: Contributing to Women’s Health - New Efforts -
Contributing to Women’s Health - New Efforts - Conceptual diagram of fund New establishment of Femtech Business Promotion Unit Purpose/Expectations Exploration (discovery of seeds) and deepening ■ Aims in establishing new unit (contributing to business) ✓ Create new business in Femtech ASKA ✓ Promot
Slide 36: Contributing to Unmet Medical Needs by RIFXIMA (rifaximin)
Contributing to Unmet Medical Needs by RIFXIMA (rifaximin) RIFXIMA sales trend Solid growth Clinical Practice Guidelines for Liver Cirrhosis 2020 projected Published in November 2020 *Financial results base (millions of yen) Strength of recommendation: Evidence level: Strongly recommended A 6,000 5,
Slide 37: A Leading Company for Thyroid Treatment
A Leading Company for Thyroid Treatment Sales trend of thyroid products*1 Sustainable growth projected Over 95% share of the domestic market for the thyroid treatment *Financial results base (millions of yen) 10,000 9,502 9,375 9,116 Background behind increase in sales of 8,432 8,768 甲状腺製品売上増加の背景 th
Slide 38: ASKA Pharmaceutical Co., Ltd.
ASKA Pharmaceutical Co., Ltd. ■ Main initiatives ・Specialty Areas ・Development Pipeline ・Overseas Business Development 38
Slide 39: Development Pipeline
Development Pipeline R&D Status (as of May 2023) Changes from last time Development code (generic name) Research*1 Non-clinical*1 PhⅠ PhⅡ PhⅢ Application Approval Indication LF111 (drospirenone) Contraception PhⅢ 実施中 PhⅢ Ongoing (Option agreement) Treatment for PMS/PMDD*2 医師主導 PhⅡ 実施中PhⅡ Ongoing Inv
Slide 40: AKP-022 (Relugolix Combination Tablet)
AKP-022 (Relugolix Combination Tablet) Relugolix Combination Tablet Licensing agreement with Takeda Pharmaceutical Company Limited. September 27, 2021 Summary Entered into a license agreement for exclusive development and commercialization for uterine fibroids in Japan. Combination of relugolix,
Slide 41: ASKA Pharmaceutical Co., Ltd.
ASKA Pharmaceutical Co., Ltd. ■ Main initiatives ・Specialty Areas ・Development Pipeline ・Overseas Business Development 41
Slide 42: Vietnam - Collaboration with Hataphar -
Vietnam - Collaboration with Hataphar - Construction progress of a new plant (in compliance with PIC/S GMP) In 2021, ASKA acquired 24.9% of Hataphar’s shares Hataphar became an affiliate company of ASKA Scheduled to be delivered in August this year Preparations for GMP acquisition started in pre
Slide 43: ASKA Animal Health Co., Ltd.
ASKA Animal Health Co., Ltd. 43
Slide 44: ASKA Animal Health - FY2023 Target and FY2022 Sales Composition
ASKA Animal Health - FY2023 Target and FY2022 Sales Composition - Sales trend of ASKA Animal Health The Medium-Term Companion animal-related *Financial results base (millions of yen) Expected to Management Plan be about the Targets Others same level as Over 6 billion yen 6,660 FY2022 0.8% 6.5% 5,630
Slide 45: ASKA Animal Health: Initiatives for FY2023
ASKA Animal Health: Initiatives for FY2023 Management Vision With strengths in breeding, immunity and nutrition in the field of livestock and fisheries, We will be the one and only company that supports the health of companion animals. Efforts in the livestock and fisheries’ area Efforts in the comp
Slide 46: ASKA Pharma Medical Co., Ltd.
ASKA Pharma Medical Co., Ltd. 46
Slide 47: ASKA Pharma Medical: Initiatives for FY2023
ASKA Pharma Medical: Initiatives for FY2023 Strength of ASKA Pharma Medical Endogenous hormone microanalysis technologies Non-invasive testing Cooperation with Partnerships with business other companies group companies Efforts to expand testing items and Business tie-up with MiRTeL Co., Ltd. Partner
Slide 48: ASKA Pharmaceutical Holdings - Group Strengths
ASKA Pharmaceutical Holdings - Group Strengths - Sources of Growth ASKA Pharmaceutical ASKA Pharmaceutical Specializing in endocrine R&D for a long time A Leading Company A Leading Company Over 100 years in Ob/Gyn field in Thyroid field Developed and launched Top sales in Ob/Gyn field* Over 95% shar
Slide 49: Become a Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company
Become a Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company Modality axis Regional axis Medical device Prevention Testing and Overseas Diagnostics Treatment Prognosis Medical life cycle axis Broad health support 49
Slide 50: For a Healthy Tomorrow and Future.
ASKA Pharmaceutical Holdings Group Corporate Message For a Healthy Tomorrow and Future. 50
Slide 51: Appendix
Appendix OC ASKA Pharmaceutical Holdings Co., Ltd. 51
Slide 52: Sales Ratio by Area and Sales Proportion of Brand-name Drugs
Sales Ratio by Area and Sales Proportion of Brand-name Drugs Sales Ratio by Area Sales Proportion of Brand-name Drugs (FY2022) ■Brand-name drugs FY2021 ■ Generic drugs Ob/Gyn ratio 30.8% FY2021 FY2022 27.2% 38.4% 50.1% 49.9％ 48.7% 51.3％ 8.6% 25.8% Aims to increase the ratio of brand-name drugs ■Obst
Slide 53: Consolidated Net Sales, Operating Profit and Operating Profit Rate
Consolidated Net Sales, Operating Profit and Operating Profit Rate 80,000 (Millions of yen) ■ Net sales ■ Operating profit 🔶 Operating profit rate 15.0% 70,000 70,000 13.0% 60,461 62,000 60,000 55,181 56,607 11.0% 52,542 50,000 46,706 8.5% 8.4% 8.7% 9.0% 8.0% 40,000 7.0% 6.5% 5,400 5,600 30,000…
Slide 54: Environmental Changes Related to Women’s Healthcare and Domestic Ob/Gyn Market Trend
Environmental Changes Related to Women’s Healthcare and The Domestic Ob/Gyn Market Trend The domestic Ob/Gyn market trend*1 Environmental Changes Related to Women (Billions of yen) Promotion of women’s advancement 94.5 Advancement in women’s participation in society 86.5 Social attention to me
Slide 55: Increase in the Number of Menstrual Cycles due to Changes in Life Events
Increase in the Number of Menstrual Cycles due to Changes in Life Events Women today experience their first menstruation earlier, tend to marry later, and experience fewer childbirths than women in past generations. The increase in the number of menstrual cycles (MCs) experienced in women's lifetime
Slide 56: Number of Uterine fibroids/Endometriosis/Dysmenorrhea Patients
Number of Uterine fibroids/Endometriosis/Dysmenorrhea Patients (Extended estimates from electronic receipt data, 12 months from January of each year to December of the following year) (Million patients) 228 225 2,500 ,000 209 196 179 2,000 ,000 1,500 ,000 146 93 100 80 1,000 ,000 500 ,0 00 0 2020 20
Slide 57: RIFXIMA: Efforts to Spread the Guidelines
RIFXIMA: Efforts to Spread the Guidelines Efforts to spread the Guidelines: Clinical Practice Guidelines for Cirrhosis Strategies in COVID-19 pandemic (Annual Review Update) Posting of domestic long-term clinical data Area Webinar plans (The following is an excerpt of addendum content) “Its efficacy
Slide 58: About Thyroid – Awareness and Main Thyroid Diseases
About Thyroid – Awareness and Main Thyroid Diseases Thyroid awareness Main thyroid diseases Hashimoto’s disease (chronic thyroiditis) This is a classic example of a disease in which secretions of thyroid hormone Do Don't know know are reduced (hypothyroidism). It is observed in one in ten adult wome
Slide 59: About Hataphar
About Hataphar Company (ハファ-社) name：Ha Tay Pharmaceutical Joint Stock Company Founded：1965 Head office: Hanoi, Vietnam Number of employees：Approx. 1000 Listed stock exchanges：Hanoi Securities Trading Center (2008) Net sales in 2022: 1,766 billion VND (9,715 million yen) Net profit in 2022: 93 billio
Slide 60: Our Initiatives for ESG Management
Our Initiatives for ESG Management Contribute toward the improvement of people's health and progress in society through the development of innovative products Environmental Social - Reduction of environmental impact - Contribution to women’s health - Environmental management - Contribution to animal
Slide 61: Productivity Improvement and Employee Engagement
Productivity Improvement and Employee Engagement In FY2022, we promoted “Work Efficiency” and “Enhanced Motivation” through the following two projects. “Head Office Working Group for Office Renewal”: The Head Office Building was renovated to create more pleasant and functional office space, and the
Slide 62: Inquiries
Inquiries Corporate Planning Department Tel : +81-3-5484-8366 e-mail: kouhou@aska-pharma.co.jp 62
ASKA Pharmaceutical Holdings — FY2022 Earnings Presentation on 6ix